Pentwater Capital Management’s Castle Biosciences CSTL Stock Holding History

Pentwater Capital Management’s Portfolio CSTL Stock Details CSTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-5,000	Closed	-$367K	–	242
2021 Q2	$367K	Sell	5,000 -3,381	-40%	-$223K	﹤0.01%	263
2021 Q1	$574K	Sell	8,381 -1,619	-16%	-$122K	0.01%	264
2020 Q4	$672K	Buy	10,000 +5,000	+100%	+$271K	0.01%	186
2020 Q3	$257K	Sell	5,000 -2,500	-33%	-$111K	﹤0.01%	209
2020 Q2	$283K	Buy	+7,500	New	+$256K	0.01%	139

Other funds holding CSTL

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

ZCI

Zevenbergen Capital Investments Edmonds, Washington $4.38B AUM 56.68% 1-Year Est. Return

Pentwater Capital Management's CSTL Position: Q3 2021 in Review

Pentwater Capital Management sold out of Castle Biosciences (CSTL) in Q3 2021, closing a stake of 5,000 shares — an estimated $367K sold.

Pentwater Capital Management first reported a position in CSTL in Q2 2020 and held it in 5 quarters. The position peaked at $672K in Q4 2020. 188 funds tracked by Wall St. Rank hold CSTL as of Q3 2021.

Pentwater Capital Management reported no remaining Castle Biosciences position as of Q3 2021 after selling out during the quarter.
Pentwater Capital Management sold 5,000 Castle Biosciences shares in Q3 2021, an estimated $367K.
Pentwater Capital Management first reported a position in Castle Biosciences in Q2 2020 and held it in 5 quarters.
Pentwater Capital Management's Castle Biosciences position peaked at $672K in Q4 2020.
188 funds tracked by Wall St. Rank held Castle Biosciences as of Q3 2021.

Based on Pentwater Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.